"Rivaximin Treatment is Beneficial for Mild Hepatic Encephalopathy", Nathan M. Bass et al., Presented at the "LIVER MEETING", OCTOBER 29 - NOVEMBER 2, 2004, Boston, Massachusetts (B1)

ZENEROLI MARIA LUISA ET AL: "Management of Hepatic Encephalopathy: Role of Rifaximin", CHEMOTHERAPY, S. KARGER AG, CH, vol. 51, no. suppl. 1, 1 April 2005 (2005-04-01), pages 90 - 95, XP008148562, ISSN: 0009-3157, DOI: 10.1159/000081994 (B1)

ANONYMOUS: "Xifaxan (rifaximin) FDA Approval History - Drugs.com", 27 May 2015 (2015-05-27), XP093013686, Retrieved from the Internet <URL:https://www.drugs.com/history/xifaxan.html> [retrieved on 20230113] (B1)

BASS ET AL: "Emerging therapies for the management of hepatic encephalopathy", SEMINARS IN LIVER DISEASE, THIEME MEDICAL PUBLISHERS, US, vol. 27, no. suppl. 2, 1 August 2007 (2007-08-01), pages 18 - 25, XP008148563, ISSN: 0272-8087, DOI: 10.1055/S-2007-984575 (B1)

BASS N M: "Review article: the current pharmacological therapies for hepatic encephalopathy.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS FEB 2007 LNKD- PUBMED:17295849, vol. 25 Suppl 1, February 2007 (2007-02-01), pages 23 - 31, XP002669397, ISSN: 0269-2813 (B1)

FARRELL DAVID J.: "Rifaximin in the Treatment of Irritable Bowel Syndrome : Is There a High Risk for Development of Antimicrobial Resistance?", JOURNAL OF CLINICAL GASTROENTEROLOGY., vol. 47, no. 3, 1 March 2013 (2013-03-01), US, pages 205 - 211, XP093013279, ISSN: 0192-0790, DOI: 10.1097/MCG.0b013e31827559a3 (B1)

GUY NEFF ET AL: "Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin", PHARMACOECONOMICS, vol. 36, no. 7, 12 April 2018 (2018-04-12), NZ, pages 809 - 822, XP055662447, ISSN: 1170-7690, DOI: 10.1007/s40273-018-0641-6 (B1)

LAWRENCE KENNETH R ET AL: "Rifaximin for the treatment of hepatic encephalopathy", PHARMACOTHERAPY, WILEY-BLACKWELL, US, vol. 28, no. 8, 1 August 2008 (2008-08-01), pages 1019 - 1032, XP008148564, ISSN: 0277-0008, [retrieved on 20120106], DOI: 10.1592/PHCO.28.8.1019 (B1)

LEEVY CARROLL B ET AL: "Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.", DIGESTIVE DISEASES AND SCIENCES MAR 2007 LNKD- PUBMED:17245628, vol. 52, no. 3, March 2007 (2007-03-01), pages 737 - 741, XP002669396, ISSN: 0163-2116 (B1)

MARSHA Y MORGAN ET AL: "The treatment of hepatic encephalopathy", METABOLIC BRAIN DISEASE, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 22, no. 3-4, 6 September 2007 (2007-09-06), pages 389 - 405, XP019554851, ISSN: 1573-7365, DOI: 10.1007/S11011-007-9060-7 (B1)

NATHAN M. BASS ET AL: "Rifaximin Treatment in Hepatic Encephalopathy", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 362, no. 12, 25 March 2010 (2010-03-25), pages 1071 - 1081, XP055616660, DOI: 10.1056/NEJMoa0907893 (B1)

PHARMAGUIDE LEBANON: "NORMIX /5ml", Retrieved from the Internet <URL:http://pharmaguidelb.com/?q=medicines/normix-5-ml-0> [retrieved on 20230203] (B1)

R WILLIAMS ET AL: "Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.", EUR J GASTROENTEROL HEPATOL, vol. 12, no. 2, 1 February 2000 (2000-02-01), pages 203 - 208, XP055408536, DOI: 10.1097/00042737-200012020-00012 (B1)

RUIZ J. ET AL: "Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 61, no. 5, 5 March 2008 (2008-03-05), GB, pages 1016 - 1019, XP093013075, ISSN: 0305-7453, DOI: 10.1093/jac/dkn078 (B1)

SALIX PHARMACEUTICALS ET AL: "Xifaxan Prescribing Information", 1 March 2008 (2008-03-01), pages 1 - 2, XP008139843, Retrieved from the Internet <URL:http://www.salix.com/assets/pdf/prescribe_into/xifaxanpi.pdf> [retrieved on 20110405] (B1)

STEVEN L. FLAMM: "Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence", THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, vol. 4, no. 3, 1 May 2011 (2011-05-01), UK, pages 199 - 206, XP055662444, ISSN: 1756-283X, DOI: 10.1177/1756283X11401774 (B1)

WO-A1-2009/108814 (B1)

ALS-NIELSEN BODIL ET AL: "Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials", BMJ, vol. 328, no. 7447, 1 May 2004 (2004-05-01), GB, pages 1046, XP093057197, ISSN: 0959-8138, DOI: 10.1136/bmj.38048.506134.EE (B1)